Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Hepatocellular carcinoma—neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome

Hepatocellular carcinoma—neoadjuvant systemic and local treatment concepts to improve... Summary Hepatocellular carcinoma (HCC) is one of the most common cancers with an increasing incidence and high mortality rate worldwide. Surgical resection is still an essential curative-intent treatment for improving the prognosis of patients with HCC. Due to the concomitance of HCC with cirrhosis, chronic liver disease, alcohol consumption and its complications, clinical treatment is challenging. Despite the rational approaches to prevention that have been developed, many patients are diagnosed at an advanced stage and are not eligible for surgical treatment, for example, because of poor underlying liver function or extrahepatic disease spread. The recurrence rates after curative resection still remain high. The implementation of neoadjuvant therapy in HCC management plays an important role in preventing tumor progression, but also shows promising results in downstaging HCC to enable surgical resection. The absence of randomized controlled trials leaves uncertainty in improving outcome, and consensus guidelines are lacking. In this review article, we summarize the clinical efficacy of evolving neoadjuvant treatments for patients with intermediate or advanced stage HCC. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Hepatocellular carcinoma—neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome

Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/hepatocellular-carcinoma-neoadjuvant-systemic-and-local-treatment-lxe9polNzi
Publisher
Springer Journals
Copyright
2022 The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-021-00791-5
Publisher site
See Article on Publisher Site

Abstract

Summary Hepatocellular carcinoma (HCC) is one of the most common cancers with an increasing incidence and high mortality rate worldwide. Surgical resection is still an essential curative-intent treatment for improving the prognosis of patients with HCC. Due to the concomitance of HCC with cirrhosis, chronic liver disease, alcohol consumption and its complications, clinical treatment is challenging. Despite the rational approaches to prevention that have been developed, many patients are diagnosed at an advanced stage and are not eligible for surgical treatment, for example, because of poor underlying liver function or extrahepatic disease spread. The recurrence rates after curative resection still remain high. The implementation of neoadjuvant therapy in HCC management plays an important role in preventing tumor progression, but also shows promising results in downstaging HCC to enable surgical resection. The absence of randomized controlled trials leaves uncertainty in improving outcome, and consensus guidelines are lacking. In this review article, we summarize the clinical efficacy of evolving neoadjuvant treatments for patients with intermediate or advanced stage HCC.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Feb 1, 2022

Keywords: oncology; medicine/public health, general

References

  • Aug 8].
    Asafo-Agyei KO, Samant H. Hepatocellular Carcinoma. [Updated
  • EASL clinical practice guidelines: management of hepatocellular carcinoma
  • Hepatocellular carcinoma: a review
    J Balogh, D Victor, EH Asham, SG Burroughs, M Boktour, A Saharia, X Li, RM Ghobrial, HP Monsour
  • Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma
    E Braunwarth, S Stättner, M Fodor, B Cardini, T Resch, R Oberhuber, D Putzer, R Bale, M Maglione, C Margreiter, S Schneeberger, D Öfner, F Primavesi
  • Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
    J Bruix, T Takayama, V Mazzaferro, GY Chau, J Yang, M Kudo, J Cai, RT Poon, KH Han, WY Tak, HC Lee, T Song, S Roayaie, L Bolondi, KS Lee, M Makuuchi, F Souza, MA Berre, G Meinhardt, JM Llovet
  • Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis
    L Kulik, JK Heimbach, F Zaiem, J Almasri, LJ Prokop, Z Wang, MH Murad, K Mohammed
  • Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis
    C Li, MD Wang, L Lu, H Wu, JJ Yu, WG Zhang, TM Pawlik, YM Zhang, YH Zhou, WM Gu, H Wang, TH Chen, J Han, H Xing, ZL Li, WY Lau, MC Wu, F Shen, T Yang
  • Preoperative strategies to improve resectability for hepatocellular carcinoma: a systematic review and meta-analysis
    F Tustumi, L Ernani, FF Coelho, WM Bernardo, SS Junior, JAP Kruger, GM Fonseca, VB Jeismann, I Cecconello, P Herman
  • Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma
    T Zhang, L Zhang, Y Xu, X Lu, H Zhao, H Yang, X Sang
  • Prospective randomized study of Doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study
    J Lammer, K Malagari, T Vogl
  • Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma
    JE Song, DY Kim
  • Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis
    JH Zou, L Zhang, ZG Ren, SL Ye
  • Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis
    S Gao, Z Yang, Z Zheng, J Yao, M Deng, H Xie, S Zheng, L Zhou
  • Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma
    K Huang, Q Zhou, R Wang, D Cheng, Y Ma
  • Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients
    A Facciorusso, R Licinio, N Muscatiello, A Leo, M Barone
  • Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma
    JR Kallini, A Gabr, R Salem, RJ Lewandowski
  • Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization
    RC Gaba, RJ Lewandowski, LM Kulik, A Riaz, SM Ibrahim, MF Mulcahy, RK Ryu, KT Sato, V Gates, MM Abecassis, RA Omary, TB Baker, R Salem
  • Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection
    M Vouche, RJ Lewandowski, R Atassi, K Memon, VL Gates, RK Ryu, RC Gaba, MF Mulcahy, T Baker, K Sato, R Hickey, D Ganger, A Riaz, J Fryer, JC Caicedo, M Abecassis, L Kulik, R Salem
  • Radioembolisation and portal vein embolization before resection of large hepatocellular carcinoma
    F Bouazza, A Poncelet, CA Garcia
  • Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials
    A Casadei Gardini, E Tamburini, M Iñarrairaegui, GL Frassineti, B Sangro
  • Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: a systematic review
    B Yang, J Liang, Z Qu, F Yang, Z Liao
  • Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma
    MJ Song
  • Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma
    JY Park, SH Ahn, YJ Yoon, JK Kim, HW Lee, DY Lee, CY Chon, YM Moon, KH Han
  • Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A
    BH Lee, DS Lee, CW Cho, SS Yun
  • Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: a retrospective cohort study
    M Hamaoka, T Kobayashi, S Kuroda, H Iwako, S Okimoto, T Kimura, H Aikata, Y Nagata, K Chayama, H Ohdan
  • Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
    M Kondo, M Morimoto, S Kobayashi
  • Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A
    BH Lee, DS Lee, CW Cho, SS Yun
  • Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase 3 trial (The FOHAIC-1 study)
    N Lyu, M Zhao
  • Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria
    FY Yao, N Mehta, J Flemming
  • Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria
    M Ravaioli, F Odaldi, A Cucchetti
  • Recent advances in systemic therapy for hepatocellular carcinoma in an aging society: 2020 update
    M Kudo
  • IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
    RS Finn, S Qin, M Ikeda, PR Galle, M Ducreux, T-Y Kim, HY Lim, M Kudo, VV Breder, P Merle, AO Kaseb, D Li, W Verret, H Shao, J Liu, L Li, AX Zhu, A-L Cheng
  • Open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
    A Kaseb, L Vence, J Blando, S Yadav
  • Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma
    A Kaseb, L Vence, J Blando, S Yadav, N Ikoma, RC Pestana, JN Vauthey, JP Allison, P Sharma
  • Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC)
    M Yarchoan, Q Zhu, JN Durham, N Gross, S Charmsaz, JM Leatherman, S Zhang, A Popovic, MJ Weiss, B Philosophe, RA Burkhart, W Burns, B Wilt, E Sugar, EJ Fertig, D Laheru, RA Anders, EM Jaffee, WJ Ho
  • Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: A randomized, open-label, multicenter controlled study
    X Wei, Y Jiang, X Zhang, S Feng, B Zhou, X Ye, H Xing, Y Xu, J Shi, W Guo, D Zhou, H Zhang, H Sun, C Huang, C Lu, Y Zheng, Y Meng, B Huang, W Cong, WY Lau, S Cheng